Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine-Reference-Cited by-同舟云学术

Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine

Published:2022-03-04 Issue:3 Volume:29 Page:
ISSN:1195-1982
Container-title:Journal of Travel Medicine
language:en
Short-container-title:

Author:

Sapkal Gajanan¹^ORCID,Kant Rajni²,Dwivedi Gaurav²,Sahay Rima R¹,Yadav Pragya D¹^ORCID,Deshpande Gururaj R¹,Singh Rajeev²,Nyayanit Dimpal A¹,Patil Deepak Y¹,Shete-Aich Anita M¹,Zaman Kamran²,Chaudhari Anil K³,Gupta Nivedita⁴,Panda Samiran⁴^ORCID,Abraham Priya¹,Bhargava Balram⁴

Affiliation:

1. Indian Council of Medical Research-National Institute of Virology (ICMR-NIV) , Pune, Maharashtra, 411021 , India

2. Indian Council of Medical Research-Regional Medical Research Centre (RMRC) , Gorakhpur, Uttar Pradesh, 273013 , India

3. Chief Medical Officer, Community Health Centre , Siddarthnagar, Uttar Pradesh, 272207 , India

4. Indian Council of Medical Research, V. Ramalingaswami Bhawan , P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029 , India

Abstract

Comparative analysis at 1- and 6-month post-vaccination showed modest reduction in S1-RBD IgG antibody and NAb titers against B.1, Alpha, Beta and Delta variants in heterologous and homologous vaccine recipients groups. However, significant reduction in NAb titers against Omicron in vaccinees’ sera post-6 months underlines need for cautious prospective follow-up.

Funder

Indian Council of Medical Research

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/jtm/advance-article-pdf/doi/10.1093/jtm/taac033/42960568/taac033.pdf

Reference9 articles.

1. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin;Kant;J Travel Med,2021

2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial;Ella;Lancet Infect Dis,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of Omicron on the COVID-19 vaccines: A review;Vacunas (English Edition);2024-04

2. The impact of Omicron on the COVID-19 vaccines: A review;Vacunas;2024-04

3. Analysis of SARS-CoV-2 genome evolutionary patterns;Microbiology Spectrum;2024-02-06

4. Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152;Indian Journal of Medical Research;2024

5. Acceptance of Annual Booster Doses of COVID-19 Vaccines Among Indian Healthcare Professionals: A Pan-India Cross-Sectional Survey;Cureus;2023-11-24